BRIEF published on 04/03/2024 at 14:05, 1 year ago Clairvoyant Therapeutics Advances Psilocybin Clinical Trial for Alcohol Use Disorder Clinical Trial Clairvoyant Therapeutics Psilocybin Treatment Alcohol Use Disorder Regulatory Pathway
BRIEF published on 04/03/2024 at 14:05, 1 year ago Clairvoyant Therapeutics fait progresser l'essai clinique sur la psilocybine pour les troubles liés à la consommation d'alcool Essai Clinique Thérapeutique Clairvoyante Traitement À La Psilocybine Trouble Lié À La Consommation D'alcool Voie Réglementaire
PRESS RELEASE published on 04/03/2024 at 14:00, 1 year ago Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization Clairvoyant Therapeutics aims to commercialize psilocybin treatment for alcohol use disorder by 2025. Company's trial progressing well, expecting results in 2024 & financing round underway Commercialization Clinical Trial Clairvoyant Therapeutics Psilocybin Treatment Alcohol Use Disorder
PRESS RELEASE published on 11/29/2023 at 13:00, 1 year 4 months ago Clairvoyant Surpasses 50 Per Cent Randomization in its Phase 2b Psilocybin Therapy Trial for Alcohol Use Disorder
PRESS RELEASE published on 03/20/2023 at 12:00, 2 years ago First Patient Dosed in Europe in Clairvoyant’s Phase 2b Clinical Trial Exploring Psilocybin Therapy as a Treatment for Alcohol Use Disorder
Published on 04/03/2025 at 15:05, 7 hours 4 minutes ago Snowline Gold Closes Fully Subscribed C$20 Million Financing Of Flow-Through Shares
Published on 04/03/2025 at 15:00, 7 hours 9 minutes ago Kingstone Insurance Partners with Kyber Technologies Inc.
Published on 04/03/2025 at 15:00, 7 hours 9 minutes ago UniDoc Announces Debt Settlement and Renews Marketing Engagement
Published on 04/03/2025 at 15:00, 7 hours 9 minutes ago Xebra Brands’ Largest Shareholder Increases Stake as Company Explores Landmark Agricultural Agreement in Mexico
Published on 04/03/2025 at 14:30, 7 hours 39 minutes ago Dominari Holdings Highlights Supporting American Companies
Published on 04/03/2025 at 18:46, 3 hours 23 minutes ago Monthly disclosure of the total number of shares and voting rights - March 2025
Published on 04/03/2025 at 18:46, 3 hours 23 minutes ago Déclaration mensuelle des actions et droits de vote – Mars 2025
Published on 04/03/2025 at 18:00, 4 hours 9 minutes ago LDC : Chiffre d'affaires 2024-2025 : 6,3 milliards d’euros, au-delà des objectifs.
Published on 04/03/2025 at 17:45, 4 hours 24 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
